JonesResearch analyst Justin Walsh lowered the firm’s price target on TFF Pharmaceuticals to $13 from $25 and keeps a Buy rating on the shares following the Q4 report. While the results for both assets were encouraging, TFF is focusing resources on advancing TFF TAC for the prevention of acute rejection in lung transplant and planning on finding strategic alternatives to advance TFF VORI, the analyst tells investors in a research note. As such, the firm removed potential revenues for TFF VORI from the model.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFFP:
- TFF Pharmaceuticals reports Q4 EPS ($2.01) vs. ($6.13) last year
- TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
- TFF Pharmaceuticals price target lowered to $44 from $56 at Roth MKM
- TFF Pharmaceuticals Shares Key Updates with Investors
- TFF Pharmaceuticals to present late-breaking abstract/data at ISHLT 2024
